CEPI begins first human trial of Bundibugyo Ebola vaccine
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced the start of the world’s first human clinical trial of a vaccine developed specifically against the Bundibugyo strain of the Ebola virus, with the first volunteer vaccinated at the University of Oxford.
The Phase I clinical trial, known as BD-Ebov, will evaluate the safety of the experimental vaccine and its ability to stimulate immune responses in healthy adult volunteers.
It said the vaccine development programme had progressed rapidly through collaboration among the University of Oxford, its Clinical BioManufacturing Facility, the Serum Institute of India (SII) and CEPI.
This is a summary of the original articles listed below. Always read the source articles for the full context. GhanaSummary does not create or modify the news — we summarise and link to original publishers.
